Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UC-MSCs in Active Systemic Lupus Erythematosus
NCT06737380Phase 1Recruiting
- Sponsor
- LiveKidney.Bio
- Start
- Jan 2025
- Primary completion
- Jun 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of umbilical cord-derived mesenchymal stromal cells in systemic lupus erythematosus (SLE), sponsored by LiveKidney.Bio. Primary endpoint: Incidence of Treatment-Emergent Adverse Events. Started Jan 2025; status: recruiting.
02
Drugs
umbilical cord-derived mesenchymal stromal cells
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06737380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06737380.